Dr Reddy’s permanently restrained by Delhi HC from commercially launching any product consisting of 'Olaparib'

Published On 2024-01-05 10:16 GMT | Update On 2024-01-05 10:18 GMT

The Delhi High Court has issued a permanent injunction against Dr. Reddy’s Laboratories Limited, restraining it from commercially launching any product containing 'Olaparib', Olaparib API, or any related product. This order came in response to an application filed by Kudos Pharmaceuticals Limited, Astrazeneca AB, and Astrazeneca Pharma India Ltd., alleging patent infringement by Dr. Reddy’s.

For more news & updates, check out the link given below:

https://medicaldialogues.in/

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Reddy’s permanently restrained by Delhi HC from commercially launching any product consisting of 'Olaparib'

Similar News